Onyx Pharmaceuticals Inc (ONXX)

[surf1944]

8:04AM Onyx Pharma: Carfilzomib demonstrates encouraging response rates in patients with relapsed and/or refractory multiple myeloma in an ongoing Phase 2 Study (ONXX) 29.77 : The co announces results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib. Results demonstrated promising overall response rates when carfilzomib was administered as a single agent in patients with relapsed and/or refractory multiple myeloma. These data were presented at the 51st annual meeting of the American Society of Hematology (ASH) in New Orleans... Overall, treatment with carfilzomib was well tolerated and no unexpected side effects occurred. The most common grade 3 treatment-related adverse events occurred in less than 5% of the patients and included fatigue, pneumonia, neutropenia, lymphopenia and anemia. Peripheral neuropathy of any grade was rare and there were no grade 4 adverse events observed.